Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes
Key takeaways
- Novo’s FDA approval of Awiqli® introduces the first once‑weekly insulin for children, opening a new revenue stream and strengthening its diabetes portfolio.
- 700 units/mL concentration
- 70,000 pharmacies nationwide
- children 10 years and older
What happened
Novo Nordisk announced that the U.S. Food and Drug Administration approved Awiqli® (insulin icodec‑abae) as the first once‑weekly basal insulin for children 10 years and older with type 2 diabetes. The drug comes in a 700‑unit/mL pen and is intended to replace the daily basal insulin injections that have been standard for pediatric patients.
Why it matters
The approval gives a new, less frequent dosing option for a growing group of young people with type 2 diabetes, potentially improving adherence and quality of life. It also expands Novo’s pediatric portfolio and positions the company as a leader in innovative diabetes therapies.
Short-term and longer-term
Short-term. In the next few days, watch for a short‑term rally as the market digests the first‑in‑class approval.
Longer-term. Over the coming months, the approval could lift Novo’s long‑term earnings by adding a new, high‑margin product line.